Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Get Free Report)'s share price traded up 6.9% on Friday . The stock traded as high as $6.03 and last traded at $6.00. 3,881,533 shares were traded during mid-day trading, a decline of 53% from the average session volume of 8,297,780 shares. The stock had previously closed at $5.61.
Wall Street Analyst Weigh In
IOVA has been the topic of a number of research analyst reports. Piper Sandler reduced their target price on Iovance Biotherapeutics from $10.00 to $7.50 and set a "neutral" rating on the stock in a research report on Friday, January 31st. HC Wainwright reissued a "buy" rating and set a $32.00 price objective on shares of Iovance Biotherapeutics in a research report on Wednesday, November 6th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat, Iovance Biotherapeutics presently has a consensus rating of "Moderate Buy" and a consensus target price of $21.07.
View Our Latest Stock Report on IOVA
Iovance Biotherapeutics Price Performance
The firm has a market capitalization of $1.63 billion, a price-to-earnings ratio of -3.58 and a beta of 0.54. The stock has a 50 day moving average price of $6.40 and a two-hundred day moving average price of $8.70.
Hedge Funds Weigh In On Iovance Biotherapeutics
Several institutional investors have recently bought and sold shares of IOVA. AlphaQuest LLC boosted its stake in shares of Iovance Biotherapeutics by 63.6% in the fourth quarter. AlphaQuest LLC now owns 4,613 shares of the biotechnology company's stock valued at $34,000 after purchasing an additional 1,794 shares during the period. SBI Securities Co. Ltd. acquired a new stake in Iovance Biotherapeutics during the 4th quarter worth approximately $36,000. GF Fund Management CO. LTD. purchased a new position in Iovance Biotherapeutics in the 4th quarter valued at approximately $47,000. One68 Global Capital LLC purchased a new position in Iovance Biotherapeutics in the 4th quarter valued at approximately $74,000. Finally, Quarry LP acquired a new position in shares of Iovance Biotherapeutics in the fourth quarter worth $74,000. 77.03% of the stock is owned by institutional investors and hedge funds.
About Iovance Biotherapeutics
(
Get Free Report)
Iovance Biotherapeutics, Inc, a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma.
Featured Articles
Before you consider Iovance Biotherapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Iovance Biotherapeutics wasn't on the list.
While Iovance Biotherapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
